Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell GILD and other ETFs, options, and stocks.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
18,000
Employees18,000
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
18,000
Employees18,000

GILD Key Statistics

Market cap
110.13B
Market cap110.13B
Price-Earnings ratio
996.62
Price-Earnings ratio996.62
Dividend yield
3.46%
Dividend yield3.46%
Average volume
8.79M
Average volume8.79M
High today
$91.98
High today$91.98
Low today
$88.21
Low today$88.21
Open price
$91.90
Open price$91.90
Volume
11.45M
Volume11.45M
52 Week high
$98.90
52 Week high$98.90
52 Week low
$62.07
52 Week low$62.07

GILD News

Benzinga 1d
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease

On Friday, Gilead Sciences, Inc. GILD revealed data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study evaluating the long-term e...

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
TipRanks 1d
Gilead announces data from interim analysis of Phase 3 ASSURE study

Gilead (GILD) Sciences announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81%, or 30 out of 37,...

Seeking Alpha 2d
Gilead, Vertex initiated as new big biotech buys at Citi

Citi has started coverage of Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) at buy saying the former will benefit from short-term growth...

Gilead, Vertex initiated as new big biotech buys at Citi

Analyst ratings

54%

of 35 ratings
Buy
54.3%
Hold
45.7%
Sell
0%

More GILD News

Seeking Alpha 3d
Gilead reports positive HIV PrEP data for lenacapavir

Gilead Sciences (NASDAQ:GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir at the HIV Glasgow...

Gilead reports positive HIV PrEP data for lenacapavir
Simply Wall St 3d
We Think You Can Look Beyond Gilead Sciences' Lackluster Earnings

Gilead Sciences, Inc.'s ( ) recent soft profit numbers didn't appear to worry shareholders, as the stock price showed strength. We think that investors might be...

We Think You Can Look Beyond Gilead Sciences' Lackluster Earnings
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.